Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$50.20 USD
-2.57 (-4.87%)
Updated Aug 5, 2025 01:53 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZLDPF 50.20 -2.57(-4.87%)
Will ZLDPF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Other News for ZLDPF
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Zealand Pharma initiated with bullish view at Wells Fargo, here's why
ClearBridge International Growth ACWI Ex-US Strategy Q2 2025 Commentary
Eli Lilly Comes Out As ADA Winner
Zealand Pharma initiated with bullish view at Barclays, here's why